Cohance Lifesciences is a science-led contract development and manufacturing partner - a CDMO - that invents, scales and supplies the chemical building blocks behind patented medicines, from early lab work to commercial production. It was assembled through a deliberate string of acquisitions under Advent International’s ownership, merging six specialist companies into one platform that now ranks among the world’s top 20 CDMOs. The recurring approach is to buy or build mastery in a handful of complex, hard-to-replicate chemistries - hazardous reactions, ultra-potent compounds, nucleic-acid synthesis - and then offer that expertise across the entire lifecycle of a drug, so that a single client can stay with the company from molecule discovery to factory-scale supply.
Business segments
A single integrated CDMO platform with three customer-facing engines - a pharma services business that works on innovators’ patented molecules, a niche API portfolio that supplies off-patent active ingredients, and a specialty-chemicals unit serving agrochemical and electronics customers - all drawing on the same chemistry backbone and manufacturing network.
1. Pharma CDMO: the innovation engine
The company makes the active ingredient, the toxic warhead that targets cancer cells, or the custom DNA-like strand for a new class of drugs - always as a paid partner to the world’s largest pharma and biotech innovators, never for its own brand.
- Paid per project, not per pill - revenue comes from development fees, milestone payments and commercial supply contracts tied to a client’s molecule; if the drug fails in trials, the work stops, so the model is inherently lumpy and non-linear.
- 19 of the top 20 innovators are clients - relationships stretching over 30 years mean the company is embedded in the supply chains of nearly every major global pharma house, with repeat business described as its most prized intangible asset.
- Chemistry that rivals fear to touch - the company specialises in hazardous reactions, high-potency compounds (HPAPIs) and complex chiral synthesis, capabilities that many peers lack or keep at arm’s length, which lets it command a premium.
- Three next-generation modalities under one roof - beyond traditional small molecules, the company is a global leader in ADC payloads (the toxic warheads attached to cancer-targeting antibodies), the world’s only commercial-scale supplier of Tricyclo-DNA building blocks for oligonucleotide drugs, and, through its US subsidiary NJ Bio, a provider of bioconjugation services that stitch the payload to the antibody.
- From gram to multi-ton scale - the company can take a molecule from early route scouting through to commercial manufacturing across 14 plants and 7 R&D facilities, with on-time delivery consistently above 95% and 22 successful US FDA audits behind it.
2. API+: the generics backbone
A portfolio of roughly 50 niche active-ingredient families where the company is a top-three supplier in eight of its ten largest molecules, sold to formulation makers rather than to patients.
- Small volumes, low competition - the business deliberately avoids blockbuster generics and instead picks complex, low-to-mid-volume APIs where fewer competitors operate, which limits the pricing swings seen in high-volume commodities.
- Backward integration builds the cost moat - by making its own starting materials and intermediates, the company drives costs down in-house rather than buying from third parties, which is how it stays competitive even when mature molecules face price pressure.
- Formulations as a bolt-on, not a storefront - the company makes finished-dose tablets and capsules for partners under profit-sharing agreements, with nearly 50 ANDAs filed, but it has no marketing arm of its own; it earns a share of the partner’s margin rather than building a consumer brand.
- A temporary factory disruption, now recovering - the Nacharam formulations plant received a US FDA warning letter that halted shipments and cost roughly ₹610 million in deferred revenue during FY26; production has resumed and remediation is underway, with alternate-site strategies keeping supply chains intact.
3. Specialty chemicals: the adjacencies bet
A smaller unit that applies the company’s chemistry skills to agrochemical active ingredients, photochromic coatings and electronic materials - serving innovators in industries far from pharma.
- Agrochemicals as a CDMO extension - the company makes advanced intermediates and active ingredients for large global agrochemical innovators, using the same project-based model as the pharma CDMO business, though it faces excess Chinese capacity and generic pressure that make cost leadership essential.
- Electronic chemicals at the evaluation stage - the company is among India’s leading manufacturers of high-purity electronic chemicals and is exploring semiconductor-linked chemistries, but these are early-stage engagements that will take time to qualify and scale.
- A dedicated site with room to grow - the segment has its own manufacturing facility in Vizag with available space for expansion, and it was recently reorganised into a standalone business unit with its own leadership and R&D team to sharpen focus.
Group structure and partners
The company is a single listed entity in India, controlled by Advent International, that has stitched together six formerly independent CDMO and API businesses - plus two strategic US subsidiaries - into one integrated platform.
- Advent International is the controlling shareholder - through a Cyprus entity, Advent acquired 50.1% of the voting shares from the founding Jasti family in September 2023, bringing the backing of a private-equity firm with USD 95 billion in assets under management.
- Built by merger, not organically - the current company was formed by amalgamating Suven Pharmaceuticals with Cohance Lifesciences (which itself had already combined RA Chem Pharma, ZCL Chemicals and Avra Laboratories), and then absorbing Casper Pharma, a greenfield oral-dosage facility.
- Leadership blends pharma veterans with private-equity operators - the executive team includes a Group CEO from the Advent ecosystem, a Pharma CDMO head recruited from Evonik’s healthcare division in New Jersey, and dedicated CEOs for the API and specialty-chemicals units.